Investigational drug · Phase 3
TGRX-678
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myeloid Leukemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "TGRX-678"
First trial start
2024
Jul 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TGRX-678", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia - Chronic Phase
- Chronic Myeloid Leukemia
- Accelerated Phase CML
Approved drugs for the same conditions: Chronic myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TGRX-678" as an intervention, largest first.
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) PatientsPivotal-lookingNot yet recruiting
Shenzhen TargetRx Co., Ltd.Industry
NCT07489755 · 180 participants (planned) · Start Apr 1, 2026 · Primary completion May 1, 2030
Drug: TGRX-678; TKI · For: Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia - Chronic Phase
- TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsActive, not recruiting
Shenzhen TargetRx Co., Ltd.Industry
NCT05434312 · 90 participants (planned) · Start Mar 29, 2021 · Primary completion Mar 2026
Drug: TGRX-678 · For: Chronic Myelogenous Leukemia
Sites: Beijing, China
Shenzhen TargetRx Co., Ltd.Industry
NCT06088888 · 90 participants (planned) · Start Jul 2, 2024 · Primary completion Dec 31, 2027
Drug: TGRX-678 · For: Chronic Myelogenous Leukemia
Sites: Houston, Texas; Seattle, Washington
Shenzhen TargetRx Co., Ltd.Industry
NCT06697899 · 76 participants · Start Nov 24, 2024 · Primary completion Jan 6, 2025
Drug: TGRX-678 · For: Chronic Myeloid Leukemia
Sites: Nanjing, China
Shenzhen TargetRx Co., Ltd.Industry
NCT06453902 · 40 participants (planned) · Start Jul 15, 2024 · Primary completion Jun 30, 2026
Drug: TGRX-678 · For: Chronic Myeloid Leukemia; Accelerated Phase CML
Sites: Beijing, China
Shenzhen TargetRx Co., Ltd.Industry
NCT06986772 · 6 participants · Start Jul 7, 2025 · Primary completion Aug 17, 2025
Drug: [14C]TGRX-678 · For: Chronic Myeloid Leukemia
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Emerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.
Motomura Y, Sasaki K · Int J Hematol 2026
- Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms.
Haddad FG, Kantarjian H · Blood Cancer J 2026
- Advances of next-generation STAMP inhibitors in chronic myeloid leukemia.
Costa A, Breccia M · Expert Opin Investig Drugs 2026
- Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1.
Shi Y, Jiang Q, Li L, et al. · Blood 2025
- Management of chronic myeloid leukemia in 2025.
Kantarjian H, Breccia M, Haddad FG, et al. · Cancer 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.